AprèsFlex®

PLT MOBILITY SOLUTIONS

MOBILITY SOLUTIONS

MOBILITY IS LIFE.

The low-dose, fast-acting, scientifically supported solution

AprèsFlex Fast Facts:

- Low, 100 mg/day dose
- Improved joint comfort in just 5 days*
- 56% reduction in WOMAC scores from baseline at 30 days*
- 69% reduction in WOMAC scores from baseline at 90 days*
- 10 pre-clinical and clinical studies
- Sustainable, botanical ingredient

Freedom to move. It's so important to the quality of our lives. AprèsFlex® 5-Day Joint Support is a proprietary, botanical ingredient that can help your customers improve mobility, rapidly and then over an extended period of time. AprèsFlex helps people manage inflammation that comes from aging, intense physical activity, and sports – so you can offer it to a broad customer base.

Around the world, people have turned to AprèsFlex more than a billion times as a drug-free approach to joint comfort and enhanced mobility. They trust the science. Trust the quality. And trust the experience.

GROWTH THROUGH INNOVATION

PLT HEALTH SOLUTIONS

EXTENSIVE SCIENTIFIC SUPPORT FOR APRÈSFLEX

AprèsFlex 5-Day Joint Support has been the subject of extensive pre-clinical and clinical studies to understand its mechanism of action and its efficacy in supporting joint comfort and mobility.

Karlapudi and colleagues examined the efficacy of AprèsFlex in the management of joint comfort and flexibility in a randomized, double-blind clinical trial.

Measurements included:

- Visual Analog Score (**VAS**) (Graph A)
- The Lequesne algofunctional index (**LFI**) (Graph B)
- The Western Ontario and McMaster Universities Osteoarthritis Index (**WOMAC**) (Graphs C,D,E)
- Various serum biomarkers (MMP3, TNF, hsCRP, COMP, CPII and C2C)

Measurements were done on Days 0, 5 and 30

The study showed that AprèsFlex:

- Provided significant reduction ($p<0.05$) in all the pain scores at five days compared to the placebo
- Provided significant reduction ($p<0.05$) in all function scores at five days compared to placebo

Previous studies with AprèsFlex showed 56% reduction in pain scores at 30 days. A similar study with AprèsFlex showed a 69% reduction in pain scores at 90 days.

Safety Studies

In Sprague Dawley rats, acute oral LD50 of AprèsFlex was determined to be > 5000 mg/kg. Acute dermal LD50 was > 2000 mg/kg. No changes in body weight or adverse effects were observed. In a subacute 28-day repeat dose toxicity study, the NOAEL was determined to be > 2500 mg/kg. No abnormal changes related to the study product were demonstrated in hematology, clinical chemistry, or histopathology. No adverse effects were observed.

Beyond joint comfort and flexibility improvements, AprèsFlex has also been shown to offer statistically significant impacct on biological markers associated with joint health and inflammation, including TNF-alpha, C-Reactive Protein (CRP), and Interleukin-6 (IL-6). It was also shown to significantly inhibit matrix metalloproteinase (MMP-3), an enzyme that breaks down cartilage, collagen, and connective tissue.



(^p<0.05)

Sustainability

A 2022 3rd party audit of the *Boswellia serrata* gum resin used to make AprèsFlex based on a broad range of environmental, cultural and economic parameters concluded: "It is clear from the information collected from the stakeholders that [sustainability] is supported. *Boswellia serrata* has several sustainability advantages that prevents over-harvesting of PLT-sourced Boswellia compared to other sources and species of Boswellia." PLT is committed to helping the communities where this ingredient is harvested thrive.

THERE'S A ROLE FOR PLT IN YOUR FORMULATION. LET US SHOW YOU THE DATA.

Studies on file. Contact us for more information at info@plthealth.com

* THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE.

Contact PLT Health Solutions for samples and more information.

+1.844-PLTHEALTH

PLT HEALTH SOLUTIONS
GROWTH THROUGH INNOVATION